Key result
Low TPM2 expression is linked to poor outcomes in lung adenocarcinoma and inhibits tumor progression.
Why the study?
There has been no study reporting TPM2 expression nor its function in lung adenocarcinoma (LUAD).
Does Tropomyosin 2 (TPM2) expression inhibit tumor progression in lung adenocarcinoma?
Does Tropomyosin 2 (TPM2) expression inhibit tumor progression in lung adenocarcinoma?
TPM2 acts as a tumor suppressor in lung adenocarcinoma and may serve as a novel prognostic biomarker.
May aid prognostication in lung adenocarcinoma; hypothesis-generating for therapeutic targeting and requires validation.
BACKGROUND: Tropomyosin 2 (TPM2), a member of the actin filament binding protein family, plays distinct roles in the progression of different cancer types. Until now, there has been no study reporting TPM2 expression nor its function in lung adenocarcinoma (LUAD). METHODS: In the present study, we examined the expression profile of TPM2 by immunohistochemistry (IHC). The clinical significance of TPM2 was assessed by univariate and multivariate analyses. Function of TPM2 in LUAD was evaluated by knockdown and overexpression strategies in three LUAD cell lines, followed by proliferation and invasion assays. Xenografts were conducted in nude mice to further validate the tumor-related role of TPM2. RESULTS: Our results showed that TPM2 was downregulated in LUAD specimens and the low expression of TPM2 was associated with poor outcomes of LUAD patients. Overexpressing TPM2 inhibited cell proliferation and invasion of LUAD cell lines, while silencing TPM2 exerted the opposite effects. The effects of TPM2 in LUAD were further confirmed by xenograft assays. CONCLUSIONS: Our results indicated that TPM2 exerted an anti-oncogenic role in LUAD via inhibiting tumor progression, thus providing a novel direction for the prognostic prediction and disease treatment.
No takes yet. Share an insight, caveat, or question.
Cui et al. (2023) studied Lung adenocarcinoma (LUAD). Tropomyosin 2 (TPM2) expression vs. Low TPM2 expression was evaluated on Clinical outcomes, cell proliferation, and invasion. Low expression of Tropomyosin 2 was associated with poor outcomes in lung adenocarcinoma, while its overexpression inhibited cell proliferation and invasion in vitro and in vivo.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: